Ashley Gallagher, MA

Of those who do not support vaccines, 79% said a major reason for their opposition is that it should be the parents’ choice about whether to vaccinate their child, and 40% cite safety concerns.

Clinical pharmacists transform diabetes care by leveraging manufacturer-sponsored patient assistance programs to dramatically improve medication access.

An ambulatory care pharmacist program in Washington State dramatically improved diabetes management by reducing A1c levels, increasing medication adherence, and providing comprehensive patient education.

ACIP also discusses COVID-19 epidemiology as well as safety and efficacy for the COVID-19 vaccines.

CD388 is being investigated as a prevention method for seasonal influenza in unvaccinated patients aged 18 to 64 years.

Nathan Ramsbacher, PharmD, emphasizes that one of the most significant barriers to clinical quality is patients' inability to access crucial medications due to cost.

The most frequent barriers to access to glucagon include cost, patient health literacy, and insurance coverage.

The initiative focuses on managing medications for high-risk diabetes patients through a collaborative drug therapy agreement.

Thimerosal is a mercury-containing compound that has been widely used as a preservative in some biological and drug products since the 1930s.

Revita is a procedure that modifies duodenal dysfunction and restores metabolic health, according to Fractyl Health.

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

Kevin Cleveland, PharmD, discusses how pharmacists are uniquely positioned to directly interact with patients, making them vital in addressing vaccine misinformation.

Investigators assessed continuous glucose monitoring with behavioral intervention for patients with type 1 diabetes.

Heidi Polek, RPh, EMBA, discusses how pharmacies must adopt strategic approaches to maintain financial health and continue providing patient care.

Emily Endres, BSPS, and Todd Sega, PharmD, MBA, discuss pressures that pharmacies are currently facing, including reimbursements, competition, and patient needs.

Laura Knockel, PharmD, BCACP, expresses concerns about how vaccine recommendations are being communicated, noting a shift away from traditional, transparent discussions to less formal channels such as social media.

Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, highlights the critical role pharmacists play in navigating vaccine recommendations and supporting patient understanding.

Deanna Tran, PharmD, BCACP, FAPhA, emphasizes community outreach, especially in areas with high vaccine hesitancy, as a crucial strategy for maintaining public trust in vaccination programs.

Bullous pemphigoid is a rare skin condition that causes large blisters filled with fluids that typically occur near skin creases, such as the upper thighs and armpits.

Pharmacists stress that rebuilding trust is challenging and requires careful, empathetic communication.

Investigators of a study used a systematic review and meta-analysis to evaluate the risk of major adverse cardiac events related to cannabis by using real-world data.

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.

The drug could also reduce chronic kidney disease when combined with insulin therapy.

In the study, the composition of the gut microbiome could also be affected by food insecurity, a known social determinant of health.

The program will include branded obesity glucagon-like peptide-1 medications, which will have a transparent monthly cost.

Investigators also found that a change in brain functional network connectivity could also be associated with type 2 diabetes risk.

Providers can prescribe the 12.5 mg and 15 mg vials of tirzepatide starting July 7, with shipments beginning in early August.

This study is the first to compare 2 biologics for patients with chronic rhinosinusitis with nasal polyps and coexisting asthma.